MENU
+Compare
MRNA
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$27.39
Change
+$0.85 (+3.20%)
Capitalization
10.59B

MRNA Moderna Forecast, Technical & Fundamental Analysis

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018... Show more

Industry: #Biotechnology
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for MRNA with price predictions
Apr 23, 2025

MRNA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for MRNA turned positive on April 21, 2025. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on MRNA as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MRNA entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.971) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (3.287) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MRNA is expected to report earnings to rise 5.84% to -307 cents per share on May 01

Moderna MRNA Stock Earnings Reports
Q1'25
Est.
$-3.08
Q4'24
Missed
by $0.18
Q3'24
Beat
by $1.95
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.48
The last earnings report on February 14 showed earnings per share of -291 cents, missing the estimate of -273 cents. With 4.74M shares outstanding, the current market capitalization sits at 10.59B.
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Technology Square
Phone
+1 617 714-6500
Employees
5600
Web
https://www.modernatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SOCL43.370.77
+1.81%
Global X Social Media ETF
HDMV34.040.28
+0.82%
First Trust Hrzn MgdVolatil Dev Intl ETF
FLGV20.450.09
+0.44%
Franklin U.S. Treasury Bond ETF
RFI11.640.03
+0.26%
Cohen and Steers Total Return Realty Fund
JAAA50.460.07
+0.14%
Janus Henderson AAA CLO ETF

MRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+3.11%
BNTX - MRNA
54%
Loosely correlated
+9.70%
RCKT - MRNA
51%
Loosely correlated
+2.44%
CVAC - MRNA
45%
Loosely correlated
-0.63%
CRSP - MRNA
43%
Loosely correlated
-1.76%
RXRX - MRNA
42%
Loosely correlated
-0.89%
More